Beyond Biotech - the podcast from Labiotech

• AION Labs is building innovative biotechs with top pharma partners in Israel

  How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can AI help drive this interest and deliver these partnerships?These are questions that this week’s guest, Mati Gill, CEO of AION Labs in Israel, is perfectly positioned to answer.AION Labs has an innovative company creation process that empowers scientists and startups to tackle high-impact pharma challenges with AI, backed by top-tier data, funding, and expertise from global pharma partners. In the middle of a transformative decade for AI-driven drug discovery, and with Israel poised to play an increasingly significant part, Mati explains how venture studios are helping to foster groundbreaking solutions for global health challenges.01:07               Meet Mati Gill07:19               The biotech industry in Israel09:38               How the Israeli biotech industry is changing with AI and other technologies13:01               The biggest challenges facing Israeli biotechs and biopharma18:07               AION Labs and its mission20:27               AION Building and AION Seeding24:03               Why top pharma wants to partner with AION Labs startups27:53               Workshopping startup ideas with top pharma companies32:04               The future of venture studios like AION Labs36:33               At the intersection of AI, biotech, and Israel’s innovation ecosystem39:24               Advice for entrepreneurs and scientistsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: AION Labs launches AI startup to improve drug trialsThe 5 hottest biotech companies making waves in IsraelWhat to look for in a biotech incubator

  --------  

  42:09

  --------

  42:09
• Navigating the biotech development journey from first steps to global scale with Lonza

  Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical companies – to transform therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Founded in 1897 in the Swiss Alps, Lonza has embraced innovation and kept pace with a fast-changing world for more than 125 years. They are a leader in both established and emerging technologies and today their 19,000 employees across more than 30 sites on five continents generate annual sales of more than $4.4 billion. We sat down with Alice Harrison, Global Technical Director (CMC and Analytics), and Megan Mason, Global Process Development Implementation Manager, to learn more about how Lonza is helping innovators large and small develop and scale their therapies and deliver better outcomes for patients worldwide._____The information in this podcast is believed to be correct at the time of recording, and is for information only. While we make reasonable efforts to ensure that the content is accurate, we make no representations or warranties of any kind regarding its accuracy, completeness, reliability, suitability or the results to be obtained from the use of such information. Lonza disclaims any liability for the use of this information and the reliance of the information contained herein is at your own risk.  _____Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: How to Set up Manufacturing for Biotech StartupsAccelerating the path to clinical filing applications with rapid toxicology material deliveryLarge molecule manufacturing: addressing challenges with strategies for success

  --------  

  50:40

  --------

  50:40
• A Finnish biotech is making progress on Parkinson's disease with support from The Michael J. Fox Foundation

  Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing symptoms – there is, as of yet, no cure. One Finnish biotech, however, is not focused on alleviating symptoms but on modifying the course of the disease itself. Their hope is to be able to stop and even reverseneurodegenerative diseases like Parkinsons, and they have the backing of significant players, such as the Michael J Fox Foundation, to do just that.This week I spoke to Antti Vuolanto, CEO of Herantis Pharma, about the work his company is doing, the science behind their approach, and the advantages and challenges of working in biotech in the Nordics.01:10               Meet Antti Vuolanto05:10               The biotech landscape in the Nordics07:07               Herantis Pharma and its mission09:38               Treating symptoms versus disease modification13:31               Herantis in relation to other Parkinson’s disease companies15:47               HER-09626:24               The global burden of Parkinson’s disease and the unmet need28:56               The role of patient and advocacy groups30:11               The future of Parkinson’s disease treatment31:52               How the Nordics can develop and expand their biotech sector36:33               Stay up to date on Herantis and their workInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Finland: Pushing biotech forward in the land of a thousand lakesParkinson’s disease: biotech’s pursuit for more therapies The stem cell race for Parkinson’s disease: Recent studies show significant promise

  --------  

  38:02

  --------

  38:02
• How RNAi is expanding from a therapy of choice for rare disease into treating common conditions

  RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions?Alnylam was the very first company to translate RNAi from Nobel Prize winning science into a commercially scalable platform. Founded in 2002, the company today has five different RNAi therapies on the market and a pipeline that continues to expand. While their early focus was on rare disease, today they are expanding into more common conditions, partnering with top pharma companies to bring next-generation therapies to market.This week I sat down with Paul Nioi, Senior Vice President of Research at Alnylam. Paul has more than 20 year’s experience in biotech and biopharma, and he walked me through Alnylam’s mission and place in the biotech ecosystem, the science of RNAi, the early success treating metabolic disease, and exactly where their platform is expanding into now and in the near future. Paul explains the capacity of RNAi to address neurological and infectious disease, the value of large-scale genomic initiatives, and how he sees drug discovery evolving in the years ahead.01:29               Meet Paul Nioi08:56               Alnylam, its mission, and its science14:35               Two types of partnerships: top pharma, and genomic initiatives22:34               RNAi therapies on the market for rare disease27:29               Expanding into more common conditions32:17               INHBE mutations and cardiometabolic disease35:01               Working with Roche to target hypertension38:58               Looking forward: Alnylam’s platform in the near future41:49               What role for national genomic initiatives?45:16               RNAi’s place in a future of precision medicineInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeuticsSix biotech companies leading the charge in hemophilia treatmentEpisode 159: Day One DNA - How and why the UK is betting on whole genome sequencing for every newborn

  --------  

  48:01

  --------

  48:01
• Are next-generation psychedelics the way forward for addressing treatment resistant depression?

  Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030. One of the most common of those mental health disorders is depressive disorder, commonly called depression, with some 280 million people suffering from either mild, moderate or severe depression.Conventional treatments for depression such as selective serotonin reuptake inhibitors, or SSRIs, can work for many people but for some suffering from treatment resistant depression, options can be limited, but some new therapies are in the clinic and might offer some hope. Beckley PsyTech is a UK biotech that is working with next-generation psychedelic-based compounds administered in a short clinic visit once every two months. With positive results from their recent Phase 2B study and a partnership with atai Life Sciences, Beckley believes they are on their way to redefining how depression is treated.01:38               Meet Cosmo Feilding03:04               Beckley PsyTech, its mission and its focus08:36               BPL-003 and next generation psychedelics11:16               Intranasal delivery and its advantages14:26               Psychedelics in the clinic and Phase IIb trial results18:32               Safety: suicide signals and adverse events21:02               Applications for psychedelics outside of depression24:11               The global economic costs of mental health disorders27:40               Comparing Beckley PsyTech to Compass Pathways and GH Research35:26               Regulatory hurdles and the stigma around psychedelics38:14               Partnering with atai Life Sciences and the future of Beckley PsyTech43:16               Milestones ahead for Beckley PsyTech45:44               A future vision for patients suffering from depressionInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: New antidepressants: tackling treatment resistant depressionPsychedelics sans side effects: neuroplastogens gain groundFrom LSD to healing minds: Where are we standing in psychedelic drug development?

  --------  

  49:07

  --------

  49:07

Więcej Wiadomości podcastów

Trendy w podcaście Wiadomości

O Beyond Biotech - the podcast from Labiotech